ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December:
WINSTON-SALEm，北卡罗来纳州，2024年11月26日（环球新闻社）- ProKidney corp.（纳斯达克：PROK）（"ProKidney"），一家专注于慢性肾病（CKD）首类细胞治疗候选药物开发的晚期临床阶段生物技术公司，今日宣布管理团队的高级成员将参加以下两项于12月举行的医疗保健会议：
|
Evercore HealthCONx Conference | |
| Date: | December 3, 2024 |
| Time: | 8:45am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
|
Citi Global Healthcare Conference | |
| Date: | December 4, 2024 |
| Format: | One-on-one meetings |
| Evercore HealthCONx会议 | |
| 日期： | 2024年12月3日 |
| 时间： | 美东时间上午8:45 |
| 格式： | 炉边聊天 |
| 网络直播： | 连接 |
| 花旗全球医疗保健大会 | |
| 日期： | 2024年12月4日 |
| 格式： | 一对一会议 |
The live webcast for the Evercore fireside chat will be accessible through the "Events" section of the Investor Relations tab within ProKidney's website at . Investors interested in one-on-one meetings should contact their Evercore and/or Citi representatives.
Evercore的炉边聊天直播将通过ProKidney网站的“投资者关系”选项卡中的“活动”部分访问。有兴趣进行一对一会议的投资者应联系Evercore和/或Citi代表。
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .
关于ProKidney公司。
ProKidney是通过细胞治疗创新治疗慢性肾病的先驱，成立于2015年经过十年的研究。ProKidney的主导产品候选药物Rilparencel（也被称为REACT）是一种首创的，拥有专利的自体细胞疗法，在第2和第3阶段的研究中评估其保护糖尿病患者肾功能的潜力。Rilparencel已获得FDA的再生医学先进疗法（RMAT）认定。欲了解更多信息，请访问。
Investor Contacts:
投资者联系方式：
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
